GLP-1 vision-loss legal information

Info@GLP1Lawsuits.com

Response within one business day

EN 中文
Free Case Review

NAION Claims

NAION Claims

Review what is publicly known about GLP-1 medicines, NAION vision-loss questions, and current lawsuit updates before deciding whether to request a free case review.

  • GLP-1 receptor agonists, NAION vision-loss questions, and semaglutide safety updates
  • EMA PRAC (June 6, 2025): recommended listing NAION as a very rare side effect (up to 1 in 10,000) for semaglutide medicines
  • MDL No. 3163 centralized in the Eastern District of Pennsylvania on Dec 15, 2025; JPML report dated Apr 1, 2026 lists 73 pending actions
Free Case Review Resource Center

Evidence context

Why GLP-1, NAION, and vision-loss questions remain under close review

This issue is being tracked across medical research, regulatory updates, and federal litigation. Read this context first, then compare it with your own timeline before deciding whether to contact.

Medical research

Public studies continue to assess GLP-1 and NAION risk signals

Retrospective studies in 2024 and 2025 raised NAION risk questions in semaglutide users, but findings remain mixed. Read this as evolving medical context before drawing individual conclusions.

Read summary

Safety updates

EMA PRAC recommended a very-rare NAION label update for semaglutide

On June 6, 2025, EMA PRAC recommended listing NAION as a very rare side effect for Ozempic, Rybelsus, and Wegovy. Safety labels can continue changing as evidence updates.

Read summary

Public litigation

MDL 3163 remains active in federal court tracking

JPML centralized these federal GLP-1 and NAION cases in the Eastern District of Pennsylvania on Dec 15, 2025. The Apr 1, 2026 pending report lists 73 pending actions.

Read summary

Latest checkpoint: Official court, EMA, and FDA sources re-checked on April 3, 2026.

Key pages

Start with these key pages

Read in order: core NAION background first, current lawsuit updates second, then relevance and next-step pages.

Eligibility and next step

Use a short relevance check before submitting a free case review.

You can still start without complete records. A rough timeline for medication use, first vision change, and eye-care visits is usually enough…

What this NAION page helps you evaluate

This page combines GLP-1 receptor agonist background, NAION vision-loss context, and the core public lawsuit updates in one reading path.

Most visitors read this context first, then compare it with their own medication and symptom timeline before deciding whether to request a free case review.

  • Start with NAION basics and GLP-1 drug context pages.
  • Then compare lawsuit updates and court-status summaries.
  • If your timeline still appears relevant, use Who May Qualify before contact.

Why this issue remains under close public review

On June 6, 2025, EMA PRAC recommended listing NAION as a very rare side effect for semaglutide medicines including Ozempic, Rybelsus, and Wegovy.

In U.S. federal court, GLP-1 and NAION lawsuits were centralized into MDL No. 3163 on December 15, 2025, and the JPML pending report dated April 1, 2026 lists 73 pending actions. Public studies remain mixed, so this issue is better read as evolving context rather than a final causation conclusion.

  • NAION is a serious optic-nerve condition discussed in the context of sudden vision loss.
  • Whether your own situation may be relevant still depends on medication history, symptom timing, and medical records.
  • Public research and regulator updates are most useful when read together.

Final next step

If your timeline still appears relevant, start with a short free case review.

The first step only needs contact details and a short timeline summary. If needed, you can review About and Resource Center pages before submitting.

Free case review is an initial screening only and does not promise any legal result.

Free Case Review Read Resource Center first